The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Here's a development that aims to keep your blood pressure in check. Literally!
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Subscribe To Our Newsletter & Stay Updated
